BBP-398
SHP2 inhibitor for MAPK/RAS driven cancers
estimated prevalence
>500,000
Disease
MAPK/RAS driven cancers
Genetic Source
PTPN11 (SHP2) and MAPK pathway
Clinical Phase
Phase 1
Modality
small molecule